{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T10:18:09Z","timestamp":1648894689894},"reference-count":10,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,10,4]]},"DOI":"10.1182\/blood-2018-08-868083","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T16:25:41Z","timestamp":1538670341000},"page":"1470-1471","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Mice no longer immune to immunomodulatory drugs"],"prefix":"10.1182","volume":"132","author":[{"given":"Flavia","family":"Pichiorri","sequence":"first","affiliation":[{"name":"City of Hope"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"14","key":"2019111910354942900_B1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","article-title":"CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice","volume":"132","author":"Fink","year":"2018","journal-title":"Blood"},{"issue":"14","key":"2019111910354942900_B2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111910354942900_B3","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111910354942900_B4","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"issue":"6168","key":"2019111910354942900_B5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"issue":"15","key":"2019111910354942900_B6","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1128\/MCB.25.15.6509-6520.2005","article-title":"Regulation of p53-MDMX interaction by casein kinase 1 alpha","volume":"25","author":"Chen","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2019111910354942900_B7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccr.2014.08.001","article-title":"Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS","volume":"26","author":"Schneider","year":"2014","journal-title":"Cancer Cell"},{"issue":"5971","key":"2019111910354942900_B8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"2","key":"2019111910354942900_B9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0041-008X(65)90095-5","article-title":"Teratogenic effects of thalidomide in rabbits, rats, hamsters, and mice","volume":"7","author":"Fratta","year":"1965","journal-title":"Toxicol Appl Pharmacol"},{"issue":"7","key":"2019111910354942900_B10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nm.4128","article-title":"Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity","volume":"22","author":"Eichner","year":"2016","journal-title":"Nat Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/14\/1470\/1406868\/blood868083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/14\/1470\/1406868\/blood868083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T18:44:12Z","timestamp":1574189052000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/132\/14\/1470\/39333\/Mice-no-longer-immune-to-immunomodulatory-drugs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,4]]},"references-count":10,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018,10,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-08-868083","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,4]]}}}